血管内皮生长因子和抗肿瘤血管新生药物研究进展  

Progress of Vascular Endothelial Growth Factor and the Antiangiogenic Drugs of Anti-Tumor

作　　者：周亚[1,2] 徐静[3] 邹检平[1,2] 

机构地区：[1]河南大学药学院,河南开封475001 [2]北京健平九星生物医药科技有限公司,北京100085 [3]北京生物制品研究所,北京100024

出　　处：《生物技术通讯》2009年第6期852-855,共4页Letters in Biotechnology

基　　金：北京市科学技术委员会科研攻关项目(Z07000200540703);北京市海淀区科学技术委员会攻关项目(K2008102)

摘　　要：肿瘤的生长与迁移离不开新血管的形成,这使得抗血管新生成为肿瘤治疗的重要途径之一。血管内皮生长因子(VEGF)是针对内皮细胞作用最强、特异性最高的血管新生促进因子,因而VEGF是抗肿瘤治疗的重要靶点。我们简要介绍了VEGF的一些生物学特点及肿瘤血管新生,着重介绍了一些抗血管新生药物的最新研究成果及其临床应用。The dependence of tumor growth and metastasis on new blood vessels makes angiogenesis a rational target for cancer therapy. Vascular endothelial growth factor（VEGF） is the important regulatory factor of angiogenesis with highest effect and specificity to the endothelial cells which makes the VEGF as an appealing target for anticancer therapy. The biochemical characteristics of VEGF and its relationship with tumor angiogenesis were introduced in this article, and the development of antiangiogenic agents and the latest clinical data were also reviewed.

关 键 词：血管内皮生长因子 肿瘤 血管新生 贝伐单抗 

分 类 号：R730[医药卫生—肿瘤] Q25[医药卫生—临床医学]